Table 4 Clinicopathologic features, therapy, and outcomes of invasive EBV+ large B-cell lymphoma in patients with breast implants.
Features | Current case | Rodriguez-Pinilla et al. | Mescam et al. | BI ALCL invasive cases (n = 5) |
|---|---|---|---|---|
Clinical features | ||||
Age (years) | 48 | 63 | 61 | Median: 57 (range: 41–72) |
Reason for implant | NA | Reconstruction | Reconstruction | Cosmetic (4), reconstruction post breast cancer (1) |
Filling of implant | Silicone | NA | NA | Saline (2), silicone (2) |
Surface of implant | NA | NA | Textured | Textured (2) |
Make of implant | NA | NA | Allergan | Allergan (1) |
Years from implantation to lymphoma | 21 | 20 | 13 | Median: 12 (range: 5–25) |
Clinical presentation | Nodularity | Local mass | Asymptomatic | Mass (2), capsule thickening (1), effusion (1), breast pain and capsule contraction (1) |
Clinical diagnosis | Tumor mass | Mass | Incidental | Mass (5) |
Pathologic features | ||||
Pattern | Sclerosis | Angiocentric | Multinodular | Multinodular (2), diffuse (2), and sclerotic and multinodular (1) |
Background cells | Small lymphocytes, histiocytes, eosinophils | Plasma cells, lymphoid follicles with germinal centers | Plasma cells, lymphoid follicles | Histiocytes (5), small lymphocytes (4), plasma cells (4), and eosinophils (4) |
Breast parenchyma invasion | Yes | NA | No (5) | |
Lymphoma cell features | Large, lobated | Large, Reed–Sternberg like cells | Plasmablastic | Large, lobated (5) |
Staging | ||||
Clinical stage | IE | IE | IE | II (3), IE (1), IIB (1) |
Pathologic stage | pT4 | pT4 | pT4 | pT4 (5) |
Therapy | ||||
Complete capsulectomy | Yes | Yes | Yes | Yes (5) |
Chemotherapy regimen | CHOP 4 cy; BEACOPP 2 cy; RT; ICE; ASCT | NA | None | CHOP 6 cy (1); CHOP 3 cy plus ICE (1); R-EPOCH plus Brentuximab (1) |
Radiation therapy | Yes | NA | None | Yes (2) |
Follow up and outcomes | ||||
Time from initial presentation (mo) | 71 | NA | 21 | median: 76 (range: 45–143) |
Time after diagnosis (mo) | 8 | 2 | 21 | median: 50 (range: 40–119) |
Outcome | CR | NA | CR | CR (4) and PR (1) |
